Gilead Sciences shares fell sharply on concerns that competition from AbbVie's hepatitis C drug puts its market share at risk.
Todd Campbell, The Motley Fool, The Motley Fool
Mon, 12/22/2014 - 2:59pm
Gilead Sciences shares fell sharply on concerns that competition from AbbVie's hepatitis C drug puts its market share at risk.